⏳ Fetching live dividend data...
Home › Calculator › SWTX Dividend Calculator 2026
SpringWorks Therapeutics, Inc. · NASDAQ
Price: $46.99 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in SWTX → $15.2K in 10 years · $51.61/month
SpringWorks Therapeutics, Inc. is a biopharmaceutical company dedicated to identifying, developing, and commercializing innovative therapies for patient populations grappling with rare diseases and various forms of cancer, often those with significant unmet medical needs. The company's most advanced experimental treatment is nirogacestat, an orally administered small molecule that functions as a gamma secretase inhibitor. This drug is currently progressing through Phase III clinical trials for the management of desmoid tumors. Another key asset in their pipeline is mirdametinib, an oral small molecule designed to inhibit MEK. It is being evaluated in Phase 2b clinical studies for neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN), and concurrently in Phase 1/2a trials for the same condition. Furthermore, mirdametinib is part of a combination regimen with lifirafenib, currently in Phase 1b/2 clinical assessment for patients with advanced or treatment-resistant solid tumors. The company is also exploring mirdametinib both as a standalone agent and in various combination strategies for solid tumors. Additionally, SpringWorks is advancing BGB-3245, an oral, selective small molecule inhibitor targeting both monomeric and dimeric forms of activating BRAF mutations, which is in Phase I development. SpringWorks has forged strategic alliances, including collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene, focusing on combination therapeutic approaches involving nirogacestat and mirdametinib. They have also secured license agreements, notably with Pfizer Inc. for nirogacestat and mirdametinib. Additional licensing deals include an arrangement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a collection of novel small molecule inhibitors of the TEA Domain, and a separate agreement with Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. Moreover, the company maintains clinical collaboration agreements with several entities, such as Janssen Biotech, Inc., Precision BioSciences, Inc., Seagen Inc., and AbbVie, Inc. Founded in 2017, SpringWorks Therapeutics, Inc. maintains its corporate headquarters in Stamford, Connecticut.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open SWTX position with:
Real after-tax yield depends on where you live and how you hold SWTX.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 4.26% | 1.46% | $426 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 3.62% | 0.82% | $362 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 3.41% | 0.61% | $341 / yr |
| 🇬🇧 UK ISA | 0% | 4.26% | 1.46% | $426 / yr |
| 🇬🇧 UK Taxable | 8.75% | 3.89% | 1.09% | $389 / yr |
| 🇨🇦 TFSA | 0% | 4.26% | 1.46% | $426 / yr |
| 🇨🇦 CA Taxable | 25% | 3.19% | 0.40% | $320 / yr |
| 🇦🇺 Super (pension) | 15% | 3.62% | 0.82% | $362 / yr |
| 🇦🇺 AU Taxable | 30% | 2.98% | 0.18% | $298 / yr |
| 🇩🇪 DE Taxable | 26.375% | 3.14% | 0.34% | $314 / yr |
| 🇫🇷 FR Taxable | 30% | 2.98% | 0.18% | $298 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
SWTX pays quarterly — 4 times per year. Next ex-div: TBD.
How SWTX compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for SWTX sourced from FMP /financial-growth endpoint — real data, not estimates.
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| D-Return | 2025-07-01 | 33,778 | — | — | ||
| D-Return | 2025-07-01 | 3,868 | $1.65 | $6.4K | ||
| D-Return | 2025-07-01 | 149,470 | $2.30 | $343.8K | ||
| D-Return | 2025-07-01 | 100,000 | $33.66 | $3.37M | ||
| D-Return | 2025-07-01 | 240,000 | $27.64 | $6.63M | ||
| D-Return | 2025-07-01 | 169,712 | — | — | ||
| D-Return | 2025-07-01 | 120,000 | $38.40 | $4.61M | ||
| D-Return | 2025-07-01 | 78,960 | $43.00 | $3.40M | ||
| D-Return | 2025-07-01 | 29,983 | $18.00 | $539.7K | ||
| D-Return | 2025-07-01 | 7,464 | $38.03 | $283.9K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the SWTX dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
SpringWorks Therapeutics, Inc. (SWTX) is currently trading at $46.99, 46% below its 52-week high. The current dividend yield is 4.26% based on an annual payout of $2.00 per share.
SpringWorks Therapeutics, Inc. (SWTX) is a healthcare stock currently trading at $46.99 with a dividend yield of 4.26%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
Auto-generated from live market data. For educational purposes only — not financial advice.
Real users. No sign-up required to leave a review.
“Finally a free dividend calculator that doesn't make me sign up or connect my brokerage. Entered SCHD and got the full DRIP projection in seconds. Bookmarked immediately.”
“I've been trying to figure out how much dividend income I'd need to retire. This tool showed me exactly — $400K in JEPI at 7% yield gives me $2,333/month. No calculator did that this clearly before.”
“Really solid passive income calculator. Covers everything: DRIP compounding, Roth IRA tax savings, DCA contributions. The year-by-year breakdown is what I was missing from other tools.”
“As someone planning retirement in 5 years, this dividend yield calculator showed me I need about 12% more in dividend stocks to hit my income target. Incredibly useful and completely free.”
“The Congress trades tracker is genius. Saw that several senators were buying O (Realty Income) and immediately ran it through the DRIP calculator. Bought 50 shares the next day.”
Reviews reflect users' personal experiences. Not financial advice.
Leave a review →If DividendFlow helped you see your future dividend income clearly, other investors deserve the same clarity. Your review takes 30 seconds and makes a real difference.
⏱️ Takes 30 seconds · No signup · Free forever